Teva and Sanofi present new outcome from Phase 2b study of duvakitug

Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025

Teva confirms efficacy and safety of Ajovy for prevention of migraine

Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month

UroGen Pharma files patent infringement action against Teva Pharmaceuticals

Teva announces approval of a generic version of Forteo in US

This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering

Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program

Phase 3 data expected in the second half of 2024

Teva Pharmaceuticals engages Honeywell to help reduce carbon impact

Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model

NATCO launches additional strengths for generic version of Revlimid in USA

Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.

Avet Pharmaceuticals appoints George Svokos as President &CEO

George Svokos joins Avet after serving as a strategic business advisor to numerous global healthcare companies

Alvotech settles with AbbVie to secure US rights to Humira biosimilar

Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023

NATCO launches first generic version of Revlimid in the US

NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene